Founded in February 2004, CNJSHDS is a High-Tech enterprise which is specially engaged in extracting, isolating and purifying paclitaxel from yew trees. Company has three key business units consisting of a chemical division for manufacturing paclitaxel, a pharma division for manufacturing formulated drugs on injection and freeze-dry injectable powder and a cultivation division for the research of yew resources. Our company invested 80,000,000 to build the chemical division. It produces paclitaxel for selling to other pharmaceutical companies to further process, and we also do paclitaxel market both home and abroad. Company has successfully established a new production line using a new method which can avoid the use of expensive solvent and taxic reagents, leading to a considerable reduction of waste.And the adoption of the technology would further enhance our competitiveness in the market. The initial designed production capacity of paclitaxel was 300kg annually. When the process optimization and the technology improvement are done, the annual production capacity will reach 500kg. The pharma division is now in construction and the total investment will be 60,000,000. It will form two product lines for producing injection and freeze-fry injectable productions. Credibility,practicalism,creativeness and competitiveness. Jiangsu Yew Biotechnology Co.,Ltd will enhance the core competitiveness and scientific innovation ability unceasingly.